Literature DB >> 2532682

The plasma endorphin, prostaglandin and catecholamine profile of patients with fibrositis treated with cyclobenzaprine and placebo: a 5-month study.

D Hamaty1, J L Valentine, R Howard, C W Howard, V Wakefield, M S Patten.   

Abstract

During a 5 month, double blind crossover study of the clinical effect of cyclobenzaprine on 7 patients with fibrositis, weekly measurements were done of plasma beta-endorphin (endorphin, prostaglandin E (PGE) and catecholamines). Endorphin levels were normal but varied with tender point tenderness. Mean plasma dopamine and PGE were elevated. Norepinephrine was normal to very high while epinephrine levels were continuously low to normal. We conclude that patients with fibrositis have a neurotransmitter plasma profile like other chronic pain states having stress and increased vasomotor activity with the possible exception of having low circulating epinephrine. This disparity may mark a failure of central nervous system pain modulation in fibrositis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2532682

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  9 in total

1.  Potential autonomic risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case-control study.

Authors:  William Maixner; Joel D Greenspan; Ronald Dubner; Eric Bair; Flora Mulkey; Vanessa Miller; Charles Knott; Gary D Slade; Richard Ohrbach; Luda Diatchenko; Roger B Fillingim
Journal:  J Pain       Date:  2011-11       Impact factor: 5.820

2.  Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.

Authors:  Kathleen C Light; Edith E Bragdon; Karen M Grewen; Kimberly A Brownley; Susan S Girdler; William Maixner
Journal:  J Pain       Date:  2009-05       Impact factor: 5.820

Review 3.  Fibromyalgia: an age-old malady begging for respect.

Authors:  R Powers
Journal:  J Gen Intern Med       Date:  1993-02       Impact factor: 5.128

Review 4.  The phenotypic and genetic signatures of common musculoskeletal pain conditions.

Authors:  Luda Diatchenko; Roger B Fillingim; Shad B Smith; William Maixner
Journal:  Nat Rev Rheumatol       Date:  2013-04-02       Impact factor: 20.543

5.  Effects of balneotherapy on serum IL-1, PGE2 and LTB4 levels in fibromyalgia patients.

Authors:  Füsum Ardiç; Merih Ozgen; Hülya Aybek; Simin Rota; Duygu Cubukçu; Ali Gökgöz
Journal:  Rheumatol Int       Date:  2007-03       Impact factor: 2.631

Review 6.  [Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].

Authors:  C Sommer; W Häuser; R Alten; F Petzke; M Späth; T Tölle; N Uçeyler; A Winkelmann; E Winter; K J Bär
Journal:  Schmerz       Date:  2012-06       Impact factor: 1.107

7.  Management of fibromyalgia syndrome: review of evidence.

Authors:  Akiko Okifuji; Bradford D Hare
Journal:  Pain Ther       Date:  2013-09-21

Review 8.  Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology.

Authors:  Sanam Kia; Ernet Choy
Journal:  Biomedicines       Date:  2017-05-08

9.  Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.

Authors:  Jarred W Younger; Alex J Zautra; Eric T Cummins
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.